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In this issue of Neuron, innovative new modifications to opioid receptors are used to expand the tools avail-
able tomodulate neuronal activity. Vardy et al. (2015) describe a new ‘‘DREADD’’ chemogenetic tool based on
the inhibitory k opioid receptor (KORD) that can be used in conjunction with already-available DREADDs.
Siuda et al. (2015) report the development of ‘‘opto-MOR,’’ a light-activatable m opioid receptor (MOR)
chimera that can be used to better understand the complexities of MOR signaling.Chemogenetics and optogenetics have
revolutionized neuroscience. These tech-
niques enable us to manipulate the activ-
ity of anatomically or genetically circum-
scribed groups of neurons in brain and
assess the physiological or behavioral
consequences. As such, the direct causal
contribution of specific populations of
neurons to physiology or behavior can
now be determined. In this issue of
Neuron, two papers describe the devel-
opment of innovative new chemogenetic
and optogenetic tools based on clever
manipulations of opioid receptor signaling
that are likely to facilitate greater under-
standing of brain function.
In the first of these two papers, Vardy
et al. (2015) describe the development of
a new chemogenetic tool to modulate
neuronal activity. DREADDs (designer re-
ceptors exclusively activated by designer
drugs) are the best-established chemo-
genetics approach currently available to
manipulate neuronal activity (Alexander
et al., 2009; Armbruster et al., 2007; Guet-
tier et al., 2009). DREADDs aremuscarinic
acetylcholine receptors (mAChRs) that
have undergone site-directed mutagen-
esis such that they no longer respond to
their endogenous agonist (acetylcholine),
but instead can be activated by cloza-
pine-N-oxide (CNO), an otherwise bio-
logically inert compound. The hM3Dq
DREADD is derived from the excitatory
M3 mAChR, whereas hM4Di is derived
from the inhibitory M4 mAChR. Stimu-
lation of hM3Dq or hM4Di by CNO in-
creases or decreases, respectively, the
excitability of neurons in which these re-ceptors have been expressed, thereby
placing their activity under experimenter
control. An important limitation to
currently available DREADDs is the fact
that the same agonist is used to activate
hM3Dq and hM4Di. As such, it is
not possible to simultaneously express
both receptors in the same neurons to
turn on or off their activity as required,
as both receptors will be activated simul-
taneously and have opposing actions on
excitability. The same limitation applies
when expressing hM3Dq and hM4Di in
different groups of neurons in the same
animal.
To overcome this limitation, Vardy et al.
(2015) sought to develop a new DREADD
whose activity can be modulated by a
different ligand. To accomplish this, they
took the same conceptual approach
used to create hM3Dq and hM4Di, but
instead of using mAChRs as the receptor
substrate they used the k-opioid receptor
(KOR). The endogenous agonist for KOR
is the opioid peptide dynorphin A. KOR
is also potently activated by salvinorin A
(SALA), but not by the SALA metabolite
salvinorin B (SALB), which is a relatively
weak agonist at KOR (IC50 250 nM).
Indeed, SALB fails to show any of the
behavioral effects commonly associated
with KOR activation, such as analgesia,
impairment of motor performance, or in-
duction of an anhedonia-like aversive
state, even after direct intracerebroven-
tricular administration. Based on in silico
modeling, Vardy and colleagues pre-
dicted that a specific mutation in KOR
(D138N) would render it insensitive toNeuronits cognate agonist dynorphin A, but
increase its sensitivity to SALB (and
SALA). Mutation of KOR to incorporate
this D138N substitution confirmed these
predictions, rendering the receptor insen-
sitive to dynorphin, but dramatically
increasing the potency of SALB at the
mutant receptor. SALB demonstrates
excellent penetration into the CNS after
systemic delivery and is inactive at
hM3Dq, hM4Di, and a broad panel of
other potential targets expressed in the
CNS, all highly desirable properties in a
chemogenetic ligand. Vardy and col-
leagues termed this new D138N-mutated
KOR and SALB combination as KORD
(k-opioid DREADD).
Next, the ability of KORD to modify
neuronal activity in vivo and impact
behavior was assessed. Vardy et al.
(2015) cloned KORD into a virus vector
in a double-floxed inverted orientation
(DiO) such that KORD could only be
expressed in the presence of Cre recom-
binase. They then tested the functional
consequences of infusing this Cre-induc-
ible KORD vector into the brains of mice
expressing Cre in different populations
of neurons with well-defined behavioral
functions. Specifically, they used appro-
priate lines of Cre-driver mice to express
KORD in GABAergic interneurons of
the ventral tegmental area and substantia
nigra (VTA/SN), paraventricular hypothal-
amus (PVH) neurons, or Agouti-related
peptide (AgRP) neurons in the arcuate
nucleus. Consistent with KORD-mediated
inhibition of neuronal activity, they found
that SALB dose-dependently increased86, May 20, 2015 ª2015 Elsevier Inc. 853
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Previewslocomotor activity in animals expressing
KORD in GABAergic neurons of VTA/SN,
consistent with their chemogenetic
silencing (van Zessen et al., 2012). SALB
also increased feeding behavior in ani-
mals expressing KORD in PVH, specif-
ically in SIM1 neurons, and decreased
food intake in animals expressing KORD
in AgRP neurons (Atasoy et al., 2012),
again consistent with KORD-mediated
inhibition of targeted neurons.
Adding to this already impressive set
of behavioral observations, Vardy et al.
(2015) next combined the infusion of
inhibitory KORD with the excitatory
hM3Dq in the same neuronal populations.
When KORD and hM3Dq were both ex-
pressed in GABAergic interneurons of
VTA/SN they found that CNO suppressed
locomotor activity and that SALB could
counteract this effect. Using the same
approach, they found that CNO induced
hyperphagia when hM3Dq was ex-
pressed in the AgRP neurons of arcuate
nucleus and that this effect was blunted
by SALB when KORD was expressed in
the same neurons. These exciting findings
suggest that KORD can be used in combi-
nation with hM3Dq in the same animal.
It is worth noting that, although SALB
did not induce any overt behavioral
effects typically seen in response to
KOR activation (analgesia, anhedonia),
SALB remains a weak endogenous KOR
agonist. It is therefore important that
doses of SALB used in vivo are kept as
low as possible to avoid possible acti-
vation of endogenous KORs. In addition,
a more detailed understanding of the
timeline and kinetics of persistent CNO-
hM3Dq signaling versus the more tran-
sient SALB-KORD effect will be needed
to better use them in combination to
manipulate neuronal activity in the most
physiologically relevant manner. Never-
theless, the development of KORD is an
exciting advance in the field that will
permit ‘‘multiplexing’’ of DREADDs such
that the activity of defined groups of
neurons can be increased or decreased
simultaneously or sequentially in the
same animal.
In the second paper in this issue of
Neuron, Siuda et al. (2015) developed a
novel light-activatable m opioid receptor
(MOR) that can be used to investigate
the spatiotemporal dynamics of MOR
signaling in vivo. Optogenetics is a854 Neuron 86, May 20, 2015 ª2015 Elsevierpowerful approach in which light-sensi-
tive anionic or cationic channels, such
as halorhodopsin and channelrhodopsin,
respectively, can be expressed in discrete
populations of neurons. Light of the
appropriate wavelength can then be
delivered to stimulate or inhibit targeted
neurons.
A major strength of optogenetics is
the precise temporal control that it can
afford over neuronal activity, enabling
endogenous patterns of cell firing to be
mimicked. However, this remarkably
precise, sub-second control of neuronal
activity can be considered a drawback
under certain circumstances. For ex-
ample, many neuromodulatory systems
in the brain act primarily through metabo-
tropic, rather than ionotropic, receptors
and exert slow (minutes or longer) alter-
ations in the firing patterns of targeted
neurons. For example, MORs are G pro-
tein-coupled receptors (GPCRs) that
inhibit the production of intracellular sec-
ond messenger systems such as cAMP.
MOR activation can also modulate ionic
flux across the plasma membrane by
influencing the activity of G protein-gated
inward rectifying potassium (GIRK) chan-
nels. Hence, opioids can induce cellular
hyperpolarization and inhibit neural activ-
ity much like inhibitory light- or ligand-
gated ion channels, but do so according
to a more gradual, but persistent, process
likely to have far different functional
consequences on neurons and circuits
compared with the more rapid effects
of ionotropic receptors (Al-Hasani and
Bruchas, 2011).
To develop an optogenetic procedure
that could better recapitulate the actions
of MOR on cell firing, Siuda et al. (2015)
capitalized on previous work showing
that hybrid GPCR constructs can be
developed that render them light acti-
vatable (Airan et al., 2009). Here, Siuda
and colleagues developed a new GPCR
chimera receptor by fusing the critical
photoisomerizing retinal binding site of
the rat rhodopsin RO4 with the intracel-
lular components of MOR to create a
hybrid light-activatable MOR, which they
termed opto-MOR. They thoroughly char-
acterized the properties of this opto-MOR
to ensure that its spatial localization
in cells matched that seen with native
MOR. They verified that light-activated
opto-MOR inhibited cAMP productionInc.and stimulated phosphorylation of extra-
cellular signaling-regulated kinase (pERK)
similar to the effects seen after agonist-
induced activation of native MOR in
cultured cells. They also found that opto-
MOR displayed light-induced functional
desensitization and internalization similar
to native MOR, consistent with opto-
MOR coupling to the canonical MOR
machinery.
Next, Siuda et al. (2015) tested the func-
tional consequences of light-induced
activation of opto-MOR in vivo by cloning
the hybrid receptor into the same type of
Cre-inducible DiO virus system described
above. They infused this virus into the
periaqueductal gray (PAG) of mice in
which Cre is expressed in inhibitory
GABAergic neurons. GABAergic neurons
in PAG are highly enriched in endogenous
MOR. In a set of elegant experiments,
they showed that opto-MOR and endo-
genous MOR converged onto the same
intracellular signaling machineries and
that stimulating native MOR with agonist
could occlude light-induced opto-MOR
signaling in PAG.
Finally, Siuda et al. (2015) turned their
attention to the behavioral effects of
light-stimulated opto-MOR activation in
brain using a real-time place conditioning
procedure. They infused the Cre-induc-
ible opto-MOR virus into the rostromedial
tegmental nucleus (RMTg) or ventral
pallidum (VP) of the mice expressing Cre
in GABAergic neurons. They found that
mice demonstrated preference for an
environment in which the GABAergic neu-
rons of the RMTg were inhibited using
photoactivation of opto-MOR. This is
consistent with the established role for
the RMTg in regulating avoidance behav-
iors (Meye et al., 2015). Conversely,
photostimulation triggered avoidance of
the light-paired chamber in mice express-
ing opto-MOR in VP GABAergic neurons
as expected.
The fact that Cre-inducible opto-MOR
can be targeted to discrete populations
of neurons, and that MOR-like signaling
can be activated specifically in these neu-
rons tomodulate behavior in the expected
manner, is an important breakthrough.
This overcomes one of the major chal-
lenges in studying MOR transmission, or
indeed the role for any receptor class in
the brain, using traditional pharmacolog-
ical approaches. Even the most selective
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PreviewsMOR agonists or antagonists cannot
distinguish between MORs expressed
at different cellular locations within the
same brain structure. For example,
MORs expressed both at pre- and post-
synaptic sites will be impacted by sys-
temic or even local administration of
pharmacological agents that can modu-
late MOR activity. Hence, opto-MOR
and other optogenetically regulated
receptors will permit unprecedented
deconvolution of receptor signaling dy-
namics in complex circuits.
KORD and opto-MOR are powerful
new tools built on the basic principles of
opioid receptor signaling. These exciting
tools will open new avenues of research
based on the multiplexed control of
discrete populations of neurons in a bidi-rectional manner and more in keeping
with the natural signaling dynamics of
neuromodulators.
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Different types of retinal ganglion cells (RGCs) project to distinct brain targets. In this issue of Neuron,
Osterhout et al. (2015) and Sun et al. (2015) identify how direction-selective RGC axons match with their
targets and the consequences for visual function when targeting is impaired.Like most sensory systems, the verte-
brate visual system is organized into
parallel channels that process distinct as-
pects of the sensory stimulus. These
channels arise in the retina, where local
circuitry isolates features of the visual
scene such as changes in light level, co-
lor, or motion in particular directions.
These features are then reported to the
brain through the firing patterns of 30
retinal ganglion cell (RGC) types, each of
which constitutes a distinct information
channel (Sanes and Masland, 2015).
What happens to these channels when
they reach the brain remains somewhat
murky. Most RGCs project along the optic
tract to the lateral geniculate nucleus and/
or the superior colliculus, but there are
dozens of additional brain regions that
receive RGC inputs—46 in mouse (Morinand Studholme, 2014). Presumably, if
the retina goes to the trouble of parsing in-
formation into distinct RGC channels,
they should project to distinct targets.
For the limited number of RGC types
that have been analyzed, we know that
their projections are indeed quite specific:
they target distinct sublayers of the genic-
ulate and colliculus, and they project to
distinct subsets of the minor retinoreci-
pient targets (Baier, 2013; Dhande and
Huberman, 2014). This finding raises the
question: what are the molecular mecha-
nisms that determine the specificity of
RGC projections? These mechanisms
are important because they ensure that
each channel of visual information is
delivered to a brain region that can make
use of it. In this issue of Neuron, two pa-
pers tackle this question, uncovering keymolecular cues for wiring one particular
visual channel, and demonstrating the
perceptual consequences when this
channel is not wired correctly (Osterhout
et al., 2015; Sun et al., 2015).
The visual pathway addressed in these
two papers has a specialized role in de-
tecting full-field motion for the purpose of
image stabilization: when the head or
body moves, the entire visual image will
shift on the retina. Motion, detected
by the retina or the inner ear, drives two re-
flexes—the optokinetic and the vestibulo-
ocular reflexes—that produce compensa-
tory eye movements to keep the image
stable and clear. TheRGCs that detect im-
age motion for the optokinetic reflex were
discovered in the rabbit in the 1960s
and have subsequently been identified in
most vertebrates (Dhande andHuberman,86, May 20, 2015 ª2015 Elsevier Inc. 855
